AA
OTLK icon

Ancora Advisors’s Outlook Therapeutics OTLK Stock Holding History

Ancora Advisors’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$226 Hold
1,100
– – ﹤0.01% 2330
2025
Q4 		$1.74K Hold
1,100
– – ﹤0.01% 2155
2025
Q3 		$1.17K Hold
1,100
– – ﹤0.01% 1754
2025
Q2 		$1.76K Hold
1,100
– – ﹤0.01% 1669
2025
Q1 		$1.34K Hold
1,100
– – ﹤0.01% 1557
2024
Q4 		$2.08K Sell
1,100
-5,000
-82% -$20.6K ﹤0.01% 1561
2024
Q3 		$32.6K Hold
6,100
– – ﹤0.01% 1093
2024
Q2 		$45K Hold
6,100
– – ﹤0.01% 971
2024
Q1 		$72.8K Hold
6,100
– – ﹤0.01% 870
2023
Q4 		$48.1K Buy
6,100
+5,000
+455% +$42.3K ﹤0.01% 954
2023
Q3 		$4.86K Sell
1,100
-4,325
-80% -$95.7K ﹤0.01% 1396
2023
Q2 		$189K Hold
5,425
– – 0.01% 664
2023
Q1 		$118K Hold
5,425
– – ﹤0.01% 747
2022
Q4 		$117K Hold
5,425
– – ﹤0.01% 792
2022
Q3 		$132K Buy
5,425
+4,325
+393% +$101K ﹤0.01% 830
2022
Q2 		$22K Buy
+1,100
New +$31.6K ﹤0.01% 1411

Other funds holding OTLK

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GWM
Gilpin Wealth Management Denver, Colorado $126M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NMC
Nine Masts Capital Central, Hong Kong $693M AUM 31.93% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return

Ancora Advisors's OTLK Position: Q1 2026 in Review

Ancora Advisors held its Outlook Therapeutics (OTLK) position steady in Q1 2026 at 1,100 shares worth $226. The position accounts for ﹤0.01% of the portfolio, ranked #2330.

Ancora Advisors first reported a position in OTLK in Q2 2022 and has held it in 16 quarters since. The position peaked at $189K in Q2 2023. 54 funds tracked by Wall St. Rank hold OTLK as of Q1 2026.

  • Ancora Advisors held 1,100 shares of Outlook Therapeutics worth $226 as of Q1 2026.
  • Ancora Advisors left its Outlook Therapeutics share count unchanged in Q1 2026.
  • Outlook Therapeutics made up ﹤0.01% of Ancora Advisors's portfolio in Q1 2026, its #2330 holding.
  • Ancora Advisors first reported a position in Outlook Therapeutics in Q2 2022 and has held it in 16 quarters since.
  • Ancora Advisors's Outlook Therapeutics position peaked at $189K in Q2 2023.
  • 54 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q1 2026.

Based on Ancora Advisors's 13F filing for Q1 2026, filed 15 May 2026.